Bayer to Make 160 Million Doses of CureVac’s mRNA Coronavirus Vaccine




In its nearly 160-year history, Bayer has never manufactured vaccines for humans. But that is changing with the Covid-19 pandemic. As part of a recently signed deal, Bayer will collaborate with German compatriot CureVac to manufacture mRNA-based coronavirus vaccine, CVnCOV, in addition to helping in R&D, supply chain management, regulatory affairs, and possible marketing operations, Stefan Oelrich, Bayer’s Pharma chief, disclosed in a press briefing on Monday. According to the plan, Bayer aims to produce 160 million doses of the CureVac shot in 2022, with the first set expected to be made available at the end of 2021. The vaccine entered phase 3 testing in December.


The work will be executed at Bayer’s Wuppertal site in Germany, Oelrich disclosed. The company recently penned a deal to sell a plant at the site to Chinese CDMO WuXi Biologics for €150 million, with Covid-19 vaccine production also featured in WuXi’s plan for use of the facility. The plan being sold to WuXi is set up to produce cell-culture-derived proteins, including vaccines, a Bayer spokesperson remarked. “We will now modify other facilities better suited to mRNA vaccine drug substance production,” the spokesperson stated.

Prior to the CureVac deal, Bayer had never manufactured vaccines for humans, but the company figures its knowledge in the development of other biologics must amount to something. “Since the announcement of our alliance between Bayer and CureVac earlier this year, we have diligently assessed our ability to further contribute with end-to-end manufacturing,” Oelrich disclosed in a prepared statement. “I am glad to report today that we have the necessary skills and capabilities at Bayer to manufacture CureVac’s mRNA-based vaccine.” CureVac previously announced it would supply “hundreds of millions” doses of its Covid-19 shot once it’s approved. The 160 million doses from Bayer will increase CureVac’s output.


Prior to the CureVac deal, Bayer had never manufactured vaccines for humans, but the company figures its knowledge in the development of other biologics must amount to something. “Since the announcement of our alliance between Bayer and CureVac earlier this year, we have diligently assessed our ability to further contribute with end-to-end manufacturing,” Oelrich disclosed in a prepared statement. “I am glad to report today that we have the necessary skills and capabilities at Bayer to manufacture CureVac’s mRNA-based vaccine.” CureVac previously announced it would supply “hundreds of millions” doses of its Covid-19 shot once it’s approved. The 160 million doses from Bayer will increase CureVac’s output.